29. Sep. 2019OÄ Dr. Angela Djanani

ESMO 2019: Kolonkarzinom – kein Benefit durch neoadjuvante Therapie

OÄ Dr. Angela Djanani, Med Uni Innsbruck, Leiterin der Arbeitsgruppe Gastrointestinale Onkologie der ÖGGH, über die negative FOxTROT-Studie, ctDNA als Prädiktor für die adjuvante Therapie, und den Vorteil von Bevacizumab bei Lebermetastasen.

Im Video diskutierte Abstracts:

  • Morton D et al. FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group. #523O
  • Taieb J et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. #LBA30_PR
  • Tarazona Llavero N et al. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype. #522O
  • Xu J et al. Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial. #LBA31